<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR34">
 <label>34.</label>
 <mixed-citation publication-type="other">Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020b;105954.</mixed-citation>
</ref>
